Pancreatic adenocarcinoma (PDA) is a highly lethal and aggressive malignancy with high mortality rates. It is critical to evaluate novel therapeutic strategies and targets for the treatment of this disease. In this article, the authors describe the important areas of focus in pancreatic cancer research, recent advances in these areas, and novel approaches that have the potential to bring about positive patient outcomes in this lethal disease. This article also focuses on recent developments in identifying new, more sensitive, and more specific blood biomarkers with potential use in the early detection of PDA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2009.11.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!